Effects of Tocilizumab in COVID-19 patients: a cohort study
COVID-19 환자에서 Tocilizumab의 효과: 코호트 연구
Observational Study
[키워드] Administered
black
Clinical improvement
cohort study
Complication
conducted
coronavirus
COVID-19
CRP
cytokine
Cytokine release syndrome
Cytokine storm
demonstrated
died
discharged
dose
early administration
early treatment
Effect
evaluated
help
Hispanic
hospital
Hospital admission
Hospitalized
Hyperinflammatory
Hyperinflammatory response
IL-6
IL-6 receptor
Infectious complications
initial
initial symptom
initial symptoms
intravenous tocilizumab
lack
male
median
median age
mitigate
Most patient
Most patients
observational study
occurred
PaO
Patient
progressive respiratory failure
randomized controlled study
receiving
reduction in
remained
Respiratory failure
Result
retrospective
SARS-CoV-2
slight increase
subsequent
supplementary material
sustained
Therapies
Tocilizumab
[DOI] 10.1186/s12879-020-05701-4 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1186/s12879-020-05701-4 PMC 바로가기 [Article Type] Observational Study